Registry of mothers and babies exposed to hepatitis C medicines in pregnancy
Follows pregnancy and birth outcomes in mothers with hepatitis C treated with direct-acting antivirals.
Key facts
- Who runs it
- The Task Force for Global Health
- Where
- Atlanta, United StatesSee the site
- Trial code
- Registry title
- The Treatment in Pregnancy for Hepatitis C ("TiP-HepC") Registry
- Status
- Recruiting
- People taking part
- 100 people, planned
- Started
- 11 Feb 2022
- Expected to end
- 30 Dec 2026
- Type of study
- Observational
- Treatments tested
- Direct Acting Antivirals
- Record updated
- 18 December 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
This registry collects health records of mothers and their babies. It is looking for mothers with chronic hepatitis C who took direct-acting antiviral (DAA) medicines during pregnancy.
- Sex
- Women with a documented pregnancy, and their babies.
- Disease stage
- Chronic hepatitis C infection, documented before or during pregnancy.
- Earlier treatment
- DAA medicine taken within 30 days of the estimated date of conception and before the pregnancy ended. The allowed DAA drugs are listed in Appendix 1 of the study.
- Biomarker or test result
- Positive test for HCV RNA or HCV core antigen.
Main reasons for not taking part
- DAA treatment that included ribavirin
- DAA treatment that included interferon
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- -Documented pregnancy with: Estimated date of conception by documentation of either 1) date of last menstrual period or 2) ultrasound evaluation Actual date of delivery
- Documented chronic HCV infection prior to or during pregnancy (positive test for HCV RNA or HCV core antigen)
- Documented DAA exposure occurring within 30 days of the estimated date of conception and before the pregnancy outcome (ie, fetal demise, spontaneous abortion, live delivery, etc). Eligible DAA drugs are listed in Appendix 1
Who cannot take part
- DAA exposures that include ribavirin or interferon will be excluded given their established harm during pregnancy
Where in United States
- The Taskforce for Global HealthAtlanta, United StatesContact: Lindsey HiebertTaking people
About the trial
What the trial wants to find out
Clinical interventions to reduce the risk of vertical transmission of hepatitis C virus (HCV) infection from mother to infant are highly limited. Direct-acting antiviral (DAA) medications have demonstrated excellent safety and efficacy in non-pregnant individuals, but there is a lack of data regarding the safety of these medications in pregnant women and the effectiveness of these medications in reducing mother-to-child transmission. Therefore, although HCV screening during pregnancy is now recommended in many countries, there is no approved treatment for HCV during pregnancy. An observational study is here proposed to assess outcomes of mother-infant pairs exposed to DAAs during pregnancy within a global clinical case registry. Data regarding the exposures and outcomes of mother-infant pairs exposed to DAAs during pregnancy will be solicited and collected from clinical providers, healthcare facilities, HCV treatment programs, and other clinical practices worldwide. Data will be shared and maintained within a secure database, and cumulative data will be analyzed at pre-determined six-month intervals. The primary outcome will be the number and proportion of mother-infant pairs with adverse pregnancy or birth outcomes. The results of this study will inform HCV treatment decisions by clinical providers and programs worldwide.
Treatments tested
- Direct Acting Antivirals
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- An Observational Study of Mother-Infant Outcomes Following Antenatal Exposure to Direct-Acting Antivirals: the Treatment in Pregnancy for Hepatitis C ("TiP-HepC") Registry
- Plain-language title
- Registry of mothers and babies exposed to hepatitis C medicines in pregnancyGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 18 December 2024